222 related articles for article (PubMed ID: 37978133)
1. Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer.
Mouw KW; Choudhury AD
Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133
[TBL] [Abstract][Full Text] [Related]
2. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract][Full Text] [Related]
3. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
4. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
[No Abstract] [Full Text] [Related]
5. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
6. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
7. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors for prostate cancer.
Longoria O; Beije N; de Bono JS
Semin Oncol; 2024; 51(1-2):25-35. PubMed ID: 37783649
[TBL] [Abstract][Full Text] [Related]
9. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
10. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitors for homologous recombination-deficient prostate cancer.
Christenson ES; Antonarakis ES
Expert Opin Emerg Drugs; 2018 Jun; 23(2):123-133. PubMed ID: 29595348
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Xu C; Mao S; Jiang H
Methods Mol Biol; 2020; 2204():75-89. PubMed ID: 32710316
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors in castration-resistant prostate cancer.
Tripathi A; Balakrishna P; Agarwal N
Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer and PARP inhibitors: progress and challenges.
Teyssonneau D; Margot H; Cabart M; Anonnay M; Sargos P; Vuong NS; Soubeyran I; Sevenet N; Roubaud G
J Hematol Oncol; 2021 Mar; 14(1):51. PubMed ID: 33781305
[TBL] [Abstract][Full Text] [Related]
15. How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients.
Sciarra A; Frisenda M; Bevilacqua G; Gentilucci A; Cattarino S; Mariotti G; Del Giudice F; Di Pierro GB; Viscuso P; Casale P; Chung BI; Autorino R; Crivellaro S; Salciccia S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614122
[TBL] [Abstract][Full Text] [Related]
16. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
17. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
Castro E; Mateo J; Olmos D; de Bono JS
Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
Niazi M; Jahangir A; Sahra S; Sattar S; Asti D; Bershadskiy A
Oncology (Williston Park); 2021 Nov; 35(11):708-715. PubMed ID: 35088974
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in
Chakraborty G; Patail NK; Hirani R; Nandakumar S; Mazzu YZ; Yoshikawa Y; Atiq M; Jehane LE; Stopsack KH; Lee GM; Abida W; Morris MJ; Mucci LA; Danila D; Kantoff PW
Clin Cancer Res; 2021 Mar; 27(6):1792-1806. PubMed ID: 33334906
[TBL] [Abstract][Full Text] [Related]
20. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
